Kyverna reports Q4/FY2025 results; cash $279M, SPS BLA on track for 1H 2026

Kyverna Therapeutics, Inc.

Net loss $37.8M Q4, $161.3M FY2025; R&D $30.0M Q4, G&A $9.3M Q4.
Cash and equivalents $279.3M; raised $147.5M in equity and $25M from loan facility.
SPS registrational trial met primary endpoints; BLA submission expected 1H 2026; launch-ready by YE 2026.
Phase 3 gMG trial enrolling; first patient Dec 2025; 14 sites active across three geographies.
Positive PMS Phase 1 data: 83% (5/6) patients achieved EDSS improvement; no high-grade CRS/ICANS.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kyverna Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.

Period: fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-126216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.